- Dr. Stephen A. Harrison
With a global rise in prevalence of non-alcoholic fatty liver disease, the need for noninvasive
tools (NITs) for the diagnosis of fibrosis and other liver injuries has been growing. That is
why we have developed LIVERFASt™, a novel blood-based noninvasive tool for the diagnosis and
staging of fibrosis, activity and steatosis.
In this webinar, Dr Stephen Harrison will present the prevalence of NAFLD,
especially in at risk population, how LIVERFASt™ is different from other NITs and how it can help
physicians in detecting and staging NAFLD, NASH and cirrhosis.
- What is LIVERFASt?
- Independent validation study
- Prognosis validation study
- LIVERFASt™ vs. other NITs
Hepatology at the Radcliffe Department of Medicine, University of Oxford, Medical
Director for Pinnacle Clinical Research and the President of Summit Clinical Research
earned his medical degree from the University of Mississippi School of Medicine. He
completed his internal medicine residency and gastroenterology fellowship at Brooke Army
Medical Center and a 4th year advanced liver disease fellowship at Saint Louis
University. He is board certified in both Internal Medicine and Gastroenterology. He is
internationally known for studies in hepatitis C and non-alcoholic fatty liver disease
with over 200 peer reviewed publications in these fields.